Phathom Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Phathom Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
  • Phathom Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$85.6M, a 97.9% decline year-over-year.
  • Phathom Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$339M, a 91.7% decline year-over-year.
  • Phathom Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$202M, a 1.96% decline from 2022.
  • Phathom Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$198M, a 37.4% decline from 2021.
  • Phathom Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$144M, a 11.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$339M -$85.6M -$42.3M -97.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$297M -$91.4M -$50.5M -123% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$247M -$82.9M -$45M -119% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$202M -$79.6M -$24.5M -44.5% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-06-14
Q3 2023 -$177M -$43.2M +$7.85M +15.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$185M -$41M +$9.96M +19.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$195M -$37.8M +$2.85M +7.01% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$198M -$55M -$19.2M -53.7% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-06-14
Q3 2022 -$179M -$51.1M -$14.4M -39.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$164M -$50.9M -$14.4M -39.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$150M -$40.7M -$5.82M -16.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$144M -$35.8M +$17.9M +33.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$162M -$36.7M -$2.56M -7.5% Jul 1, 2021 Sep 30, 2021 10-Q/A 2022-11-09
Q2 2021 -$159M -$36.6M -$15.5M -73.2% Apr 1, 2021 Jun 30, 2021 10-Q/A 2022-11-09
Q1 2021 -$144M -$34.8M -$14.7M -73% Jan 1, 2021 Mar 31, 2021 10-Q/A 2022-11-09
Q4 2020 -$129M -$53.7M +$44.3M +45.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-30
Q3 2020 -$173M -$34.1M +$34M +49.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$207M -$21.1M +$66.7M +76% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$274M -$20.1M -$18.9M -1510% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$255M -$98M -$97.5M -20149% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$158M -$68.1M -$67.8M -23387% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-30
Q2 2019 -$89.8M -$87.8M -$87.5M -33655% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-30
Q1 2019 -$2.29M -$1.25M -$997K -393% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-30
Q4 2018 -$1.29M -$484K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-19
Q3 2018 -$290K Jul 1, 2018 Sep 30, 2018 10-K 2020-03-19
Q2 2018 -$260K Apr 1, 2018 Jun 30, 2018 10-K 2020-03-19
Q1 2018 -$254K Jan 1, 2018 Mar 31, 2018 10-K 2020-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.